Shares Homepage - BSE Sensex, NSE Nifty, Latest Prices, Live News, Company Search, Result Annoucements, Company News, Top stories, Gainers Losers, Top Performers, Market Commentary, Live Quotes, Bulk Deals
India's preferred Personal finance destination
Home Shares News Centre F&O Mutual Funds IPO Portfolio Commodity Loans Financial Planning Insurance About Us
Markets Companies Research Industries E-Mail Page
Wealth Tracker      Tax Corner NRI Centre Chat Masala Feedback
my Last 5 Scrips
Company BSE Price(Rs) % Chg
Wipro Lt 559.50 3.82
Tata Stl 458.95 0.40
Tata Pow 88.00 0.28
Ong Corp 403.25 0.80
Hindalco 149.65 0.81
Clear All Clear Last
Shares
NSE Live
Nifty Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
BSE Live
BSE30 Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Market Pulse
Leaders
Laggards
FII Activity
Mutual Fund Activity
Meetings
Results Watch
Results Calendar
Results Announced
IPO Watch
Company
Snapshots
Quotes
Charts
Financials
Recent News
Broker Research
Meetings
Research Tutorial
Discussion Forum
Research
Research Reports
Sector Watch
Economy Watch
Snapshot-Wockhardt Limited
Wockhardt Limited
Sector:Pharmaceuticals Pharmaceuticals - Formulations
BSE:532300NSE:WOCKPHARMABloomberg:WPL@INReuters:WCKH.BO
Market Lot: 1Face Value: 5ISIN Demat: INE049B01025
QuotesSnapshotChartsFinancialsResearchRecent News
Peer GroupAGM/AMMF HoldingDiscussion ForumBSE/NSE NoticesBSE/NSE Deals

 
 
Recent Developments
01-SEP-14 Wockhardt, one of the leading pharmaceutical and biotechnology company, announced that its New Drug Discovery program in Anti-Infective research received a major boost after two of its drugs, WCK 771 and WCK 2349, received the coveted Qualified Infectious Disease Product (QIDP) status from the US FDA. This is the first instance of an Indian Pharmaceutical company receiving a QIDP status. 12-AUG-14 Wockhardt, one of the leading pharma...   More..
Business Profile Future Plans
CEO Talk
Wockhardt Ltd is exploring possibilities of co-licensing WCK-771 and WCK-919. The company intends to focus essentially on the anti-infective therapeutic segment as it accounts for 12 per cent of the total pharma market and is the third largest therapeutic segment.   Habil Khorakiwala
One To One
Recent news
Latest News
USFDA grants QIDP status for Wockhardt drugs  -IRIS 01-Sep-14
Previous

More


Brief Financials (in Rs. Mn.)Detailed Quarterly
Period ending (months)30-Jun-2014(3)31-Mar-2014 (12)31-Mar-2013 (12)
Net sales 4854.4018052.7024711.80
Other Income17.902787.40653.40
Total Income4872.3020840.1025365.20
Cost of goods sold4540.1017392.6018998.20
OPBDIT332.203447.506367.00
PAT53.501986.106227.00
Gross Block---
Equity capital550.00548.80547.90
EPS (Rs.)-18.1056.88
DPS (Rs.)---
BV (Rs.)---
P/E range (x)-18.60 - 114.3610.51 - 38.08
Debt / Equity (x)---
Operating margin (% of OI) 6.816.525.1
Net margin (% of OI) 1.1 9.524.5
Detailed Financials
Income 
Statement
Balance Sheet Latest 
Quarterly/Halfyearly
Ratio Analysis Share Statistics
Price Charts
Scrip Information



Registered Office
ADDRESS
Wockhardt Towers
Bandra Kurla Complex
Bandra (East)
Mumbai
Maharashtra-400 051
PHONE
(022) 2653 4444
FAX
(022) 2653 4242
 
Board of Directors
Board Meetings
Date Purpose
03-NOV-14 Quarterly Results & Interim Dividend
NSE/BSE Announcements


Home | Shares | F&O | Mutual Funds | Loans | Insurance | News Centre
Wealth Tracker | Tax Corner | NRI Centre | Search in myiris | Advertise
All rights reserved. IRIS Business Services Limited
Disclaimer